New York: Intra-Cellular Therapies (NASDAQ:ITCI) Stock Has Just Had Its Buy Rating Reiterated by Cowen & Co.. Shares now Have a $27.0 Target

September 13, 2017 - By Ellis Scott

 New York: Intra Cellular Therapies (NASDAQ:ITCI) Stock Has Just Had Its Buy Rating Reiterated by Cowen & Co.. Shares now Have a $27.0 Target

Investors sentiment increased to 1.46 in 2016 Q4. Its up 0.52, from 0.94 in 2016Q3. It increased, as 25 investors sold ITI Inc shares while 23 reduced holdings. 27 funds opened positions while 43 raised stakes. 29.52 million shares or 8.32% more from 27.25 million shares in 2016Q3 were reported.

Quantbot Lp holds 0.01% or 3,864 shares. Kcg Hldg accumulated 30,368 shares. Baker Bros Advsrs L P holds 609,166 shares or 0.09% of its portfolio. Blackrock holds 0% or 14,805 shares in its portfolio. Schwab Charles Invest Incorporated has 0% invested in ITI Inc (NASDAQ:ITCI) for 130,640 shares. Manufacturers Life Insur Com The has invested 0% in ITI Inc (NASDAQ:ITCI). Blackrock Fund Advsr stated it has 2.03M shares. 57,381 are held by Blackrock Group Ltd. Moreover, Tower Research Cap Ltd Limited Liability Company (Trc) has 0.01% invested in ITI Inc (NASDAQ:ITCI) for 5,762 shares. Goldman Sachs Group invested in 83,300 shares or 0% of the stock. Gemmer Asset Mngmt Limited Liability holds 0.04% of its portfolio in ITI Inc (NASDAQ:ITCI) for 5,000 shares. Blume Cap invested in 0.01% or 1,000 shares. Parametric Port Associate Ltd Liability owns 17,944 shares. Bogle Inv Lp De reported 453,534 shares or 0.47% of all its holdings. Gam Ag stated it has 0.01% of its portfolio in ITI Inc (NASDAQ:ITCI).

Intra-Cellular Therapies (NASDAQ:ITCI) Rating Reaffirmed

In a report revealed to investors on Friday, 8 September, The Buy rating of Intra-Cellular Therapies (NASDAQ:ITCI) shares was maintained at Cowen & Co., who now has a $27.0 target price per share on the stock. Cowen & Co.’s target price per share means a possible upside of 31.64 % from the last stock close price of the company.

Investors sentiment increased to 1.46 in 2016 Q4. Its up 0.52, from 0.94 in 2016Q3. It increased, as 25 investors sold ITI Inc shares while 23 reduced holdings. 27 funds opened positions while 43 raised stakes. 29.52 million shares or 8.32% more from 27.25 million shares in 2016Q3 were reported.

Quantbot Lp holds 0.01% or 3,864 shares. Kcg Hldg accumulated 30,368 shares. Baker Bros Advsrs L P holds 609,166 shares or 0.09% of its portfolio. Blackrock holds 0% or 14,805 shares in its portfolio. Schwab Charles Invest Incorporated has 0% invested in ITI Inc (NASDAQ:ITCI) for 130,640 shares. Manufacturers Life Insur Com The has invested 0% in ITI Inc (NASDAQ:ITCI). Blackrock Fund Advsr stated it has 2.03M shares. 57,381 are held by Blackrock Group Ltd. Moreover, Tower Research Cap Ltd Limited Liability Company (Trc) has 0.01% invested in ITI Inc (NASDAQ:ITCI) for 5,762 shares. Goldman Sachs Group invested in 83,300 shares or 0% of the stock. Gemmer Asset Mngmt Limited Liability holds 0.04% of its portfolio in ITI Inc (NASDAQ:ITCI) for 5,000 shares. Blume Cap invested in 0.01% or 1,000 shares. Parametric Port Associate Ltd Liability owns 17,944 shares. Bogle Inv Lp De reported 453,534 shares or 0.47% of all its holdings. Gam Ag stated it has 0.01% of its portfolio in ITI Inc (NASDAQ:ITCI).

ITI Inc (NASDAQ:ITCI) Ratings Coverage

Among 10 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Intra-Cellular Therapies has $104 highest and $1000 lowest target. $61.33’s average target is 199.02% above currents $20.51 stock price. Intra-Cellular Therapies had 31 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Tuesday, June 6 by Cowen & Co. Cowen & Co maintained it with “Buy” rating and $20.0 target in Wednesday, August 23 report. The firm has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald. Leerink Swann downgraded the stock to “Market Perform” rating in Tuesday, May 2 report. The company was upgraded on Wednesday, August 30 by Ladenburg. The firm has “Buy” rating by Guggenheim given on Thursday, September 17. The stock of ITI Inc (NASDAQ:ITCI) has “Hold” rating given on Wednesday, August 9 by Piper Jaffray. On Friday, November 6 the stock rating was maintained by RBC Capital Markets with “Outperform”. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 9 report. The rating was downgraded by Ladenburg Thalmann on Tuesday, May 2 to “Neutral”.

About 237,320 shares traded. ITI Inc (NASDAQ:ITCI) has declined 68.76% since September 13, 2016 and is downtrending. It has underperformed by 85.46% the S&P500.

ITI Inc. is a United States-based company. The company has market cap of $890.85 million.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.